<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Vitamin B6 (pyridoxine): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Vitamin B6 (pyridoxine): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Vitamin B6 (pyridoxine): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12049" href="/d/html/12049.html" rel="external">see "Vitamin B6 (pyridoxine): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12753" href="/d/html/12753.html" rel="external">see "Vitamin B6 (pyridoxine): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F216001"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Neuro-K-250 T.D. [OTC] [DSC];</li>
<li>Neuro-K-250 Vitamin B6 [OTC] [DSC];</li>
<li>Neuro-K-50 [OTC] [DSC];</li>
<li>Neuro-K-500 [OTC] [DSC];</li>
<li>True Vitamin B6 [OTC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F216041"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Vitamin, Water Soluble</li></ul></div>
<div class="block doa drugH1Div" id="F216003"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="58b7e4a2-3026-41f5-bbc1-788168a37b5c">Pyridoxine deficiency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pyridoxine deficiency:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dietary deficiency:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM, IV:</b> 10 to 20 mg daily for 3 weeks, followed by daily oral therapy (2 to 5 mg per day which can be obtained from a multivitamin product) for several weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 25 to 100 mg daily for 1 to 2 weeks (DiBaise 2019; ESPEN [Berger 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pyridoxine-dependency syndromes</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Initial: Acute, active seizure:<i></i>
<b>IV: </b>100 mg as a single dose; repeat as needed at 5- to 10-minute intervals up to a total dose of 500 mg (Vossler 2020).</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance: <b>Oral: </b>200 to 500 mg daily (maximum: 500 mg/day) (Coughlin 2021; Stockler 2011).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3e247df1-b12b-4c66-828a-0337150d4c4e">Ethylene glycol poisoning</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ethylene glycol poisoning (off-label use): Note:</b> Cofactors are adjunctive to antidotal therapy and should never be used alone.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 100 mg per day until the intoxication has resolved (Howland 2019).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b8b066f7-baf0-44ee-92dc-bbd4debb5ee3">Gyromitrin-containing mushroom overdose/toxicity</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gyromitrin-containing mushroom (false morel) overdose/toxicity (treatment/prophylaxis) (off-label use): Note:</b> Dosing recommendations are based on the use of pyridoxine for the treatment and prevention of neurological toxicities associated with isoniazid overdose (Goldfrank 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Initial: 5 <b>g</b>; administer at a rate of 0.5 to 1 <b>g</b>/minute; may repeat every 5 to 10 minutes as needed to control persistent seizure activity and/or CNS toxicity (Howland 2019; Morrow 2006).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fe01fbe7-46e3-46d7-908e-f5ad985f2d8f">Hydrazine toxicity</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hydrazine toxicity (off-label use): Note:</b> Optimal dose has not been established; dosing recommendations are based on the use of pyridoxine for the treatment and prevention of neurological toxicities associated with isoniazid overdose (Howland 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Initial: 5 <b>g</b>; administer at a rate of 0.5 to 1 <b>g</b>/minute; may repeat every 5 to 10 minutes as needed to control persistent seizure activity and/or CNS toxicity (Howland 2019; Morrow 2006; Nagappan 2000).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8ad4605e-60e2-416f-ab7e-545de22137af">Nausea and vomiting, pregnancy associated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nausea and vomiting, pregnancy-associated (off-label use): Note: </b>Indicated as monotherapy in conjunction with nonpharmacologic measures for nausea alone; combination with doxylamine may be considered when nausea persists despite nonpharmacologic measures and pyridoxine monotherapy <b>or </b>as initial therapy for more severe symptoms (eg, nausea with vomiting) (ACOG 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 12.5 to 25 mg 3 to 4 times per day as monotherapy or in combination with doxylamine (ACOG 2018; Smith 2022).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="652c0103-9244-47e1-b037-773b92c42404">Neurological toxicities associated with isoniazid overdose</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neurological toxicities (ie, seizures, coma) associated with isoniazid overdose (off-label use): Note:</b> As isoniazid poisonings are rare, hospitals may not have sufficient quantities of parenteral pyridoxine available for IV administration (preferred); pyridoxine tablets may be crushed and made into a slurry and given at the same dose orally or via NG tube (Bateman 2016; Hernon 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Treatment: </b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Acute ingestion of known amount: </i>
<b>IV: </b> Initial: A total dose of pyridoxine equal to the amount of isoniazid ingested (maximum dose: 5 g); administer at a rate of 0.5 to 1 g/minute until seizures stop or the maximum initial dose has been administered; may repeat every 5 to 10 minutes as needed to control persistent seizure activity and/or CNS toxicity. If seizures stop prior to the administration of the calculated initial dose, infuse the remaining pyridoxine over 4 to 6 hours (Howland 2019; Morrow 2006).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Acute ingestion of unknown amount:</i>
<b>IV: </b>Initial: 5 g; administer at a rate of 0.5 to 1 g/minute; may repeat every 5 to 10 minutes as needed to control persistent seizure activity and/or CNS toxicity (Howland 2019; Morrow 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Prevention: </b></i>
<b>IV:</b> Asymptomatic patients who present within 2 hours of ingesting a potentially toxic amount of isoniazid should receive a prophylactic dose of pyridoxine (Hernon 2019). Dosing recommendations are the same as for the treatment of symptomatic patients.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa5440b2-816a-406c-a3b0-a49be1c06e77">Peripheral neuropathy associated with isoniazid therapy for <i>Mycobacterium</i>
<i>tuberculosis </i></span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peripheral neuropathy associated with isoniazid therapy for</b>
<b>
<i>Mycobacterium tuberculosis</i></b>
<b> (prevention): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Daily isoniazid regimen: </i>
<b>Oral:</b> 25 to 50 mg/day (CDC [Kaplan 2009]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weekly isoniazid/rifapentine regimen: </i>
<b>Oral: </b>50 mg once weekly (HHS [adult OI 2020]).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991122"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50988440"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doe drugH1Div" id="F216004"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F216023"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12753" href="/d/html/12753.html" rel="external">see "Vitamin B6 (pyridoxine): Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d15818cf-6a3e-41ef-b02b-773a5e5d54c5">Pyridoxine deficiency; treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pyridoxine deficiency; treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children: Oral, IM, IV: 5 to 25 mg/day for 3 weeks, then 2.5 to 5 mg/day in multivitamin product (Gal 2007).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: Oral, IM, IV: 10 to 20 mg/day for 3 weeks, then 2 to 5 mg/day (usual dosage found in multivitamin products) (Gal 2007).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5a39cbfb-6aa5-4b4e-b77d-0bd190b8626c">Pyridoxine-dependent seizures, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pyridoxine-dependent seizures, treatment:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial: Acute, active seizure:</i>
<b>Note: </b> Administration should occur in intensive care unit due to possible apnea episodes (may require intubation); with oral administration, therapeutic response and adverse effect (ie, apnea) may be delayed in presentation; monitor patients closely (Stockler 2011).</p>
<p style="text-indent:-2em;margin-left:8em;">IV (preferred): 100 mg/dose; may repeat dose over the course of 30 minutes (Stockler 2011).</p>
<p style="text-indent:-2em;margin-left:8em;">Oral (when IV not feasible): 30 mg/kg/day for several days (Stockler 2011).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance</i>: Oral: Usual dose: 15 to 30 mg/kg/day not to exceed 500 mg/day (Baxter 1999; NORD 2017; Stockler 2011).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="67112733-e3a8-4e64-9ace-2ce6385ca15a">Drug-induced deficiency; chronic use</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Drug-induced deficiency (cycloserine, isoniazid, penicillamine); chronic use:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Isoniazid/Cycloserine: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Prevention: <b>Note:</b> Recommended for patients at risk: Exclusively breastfed infants, meat- and milk-deficient diet, nutritional deficiency, pregnant adolescents, HIV-infected patients (HHS [OI pediatric 2019]); <i>Red Book </i>[AAP 2018]).</p>
<p style="text-indent:-2em;margin-left:8em;">Infants and Children: Oral: 1 to 2 mg/kg once daily; maximum daily dose: 50 mg/<b>day</b> (HHS [OI pediatric 2019]).</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents: Oral: 25 to 50 mg/day (ATS/CDC/IDSA [Nahid 2016]); HHS [OI adult 2019]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Penicillamine (in Wilson Disease patients):</i> Limited data available: Children and Adolescents: Oral: 25 to 50 mg/day (Roberts 2008).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="abbc8f3b-8807-4a0e-ba13-6497905297aa">Acute isoniazid ingestion</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute isoniazid ingestion: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment of isoniazid-induced seizures and/or coma</i>: IV: Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Acute ingestion of known amount: Initial: A total dose of pyridoxine equal to the amount of isoniazid ingested (maximum dose: 70 mg/kg up to 5 g); administer at a rate of 0.5 to 1 g/minute until seizures stop or the maximum initial dose has been administered; may repeat every 5 to 10 minutes as needed to control persistent seizure activity and/or CNS toxicity. If seizures stop prior to the administration of the calculated initial dose, infuse the remaining pyridoxine over 4 to 6 hours (Howland 2015; Morrow 2006).</p>
<p style="text-indent:-2em;margin-left:6em;">Acute ingestion of unknown amount: Initial: 70 mg/kg (maximum dose: 5 g); administer at a rate of 0.5 to 1 g/minute; may repeat every 5 to 10 minutes as needed to control persistent seizure activity and/or CNS toxicity (Howland 2015; Morrow 2006; Santucci 1999)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prevention of isoniazid-induced seizures and/or coma:</i> IV: Children: Asymptomatic patients who present within 2 hours of ingesting a potentially toxic amount of isoniazid should receive a prophylactic dose of pyridoxine (Hernon 2015). Dosing recommendations are the same as for the treatment of symptomatic patients.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="76ea6571-cdf2-4dc3-86c9-beeab89f6fa0">Acute intoxication; mushroom ingestion</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute intoxication; mushroom ingestion (genus </b>
<i>
<b>Gyromitra</b></i>
<b>):</b> Children and Adolescents: IV: 25 mg/kg/dose; repeat as necessary to a maximum total dose of 15 to 20 g (Berger 2005).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51159535"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51159536"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F215969"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Ataxia, drowsiness, headache, neuropathy, paresthesia, seizure (following very large IV doses)</p>
<p style="text-indent:-2em;margin-left:2em;">Endocrine &amp; metabolic: Acidosis, folate deficiency</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Nausea</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic: Increased serum AST</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity: Hypersensitivity reaction</p></div>
<div class="block coi drugH1Div" id="F215986"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Injection: Hypersensitivity to pyridoxine or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F215966"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Neuropathy: Severe, permanent peripheral neuropathies have been reported; risk may be increased with chronic use or higher doses (eg, &gt;500 mg/day) (Albin 1987; Coughlin 2021).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Aluminum: The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal impairment. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register 2002). See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Dependence/withdrawal: Doses &gt;200 mg/day may cause dependence and withdrawal.</p>
<p style="text-indent:-2em;margin-left:4em;">• Vitamin deficiency: Single vitamin deficiency is rare; evaluate for other deficiencies.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F54180100"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Higher doses (oral doses &gt;30 mg/kg/day) have been associated with sensory and rare motor neuropathies, both of which are potentially reversible (Stockler 2011). Neuropathies have also been described with chronic administration of doses as low as 50 mg/day; however, some patients do not experience neuropathy (at low or high doses), even after years of administration (McLachlan 1995; Stockler 2011).</p></div>
<div class="block foc drugH1Div" id="F215977"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Neuro-K-250 T.D.: 250 mg [DSC] [corn free, rye free, starch free, sugar free, wheat free]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Neuro-K-50: 50 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Neuro-K-500: 500 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Neuro-K-250 Vitamin B6: 250 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">True Vitamin B6: 10 mg, 25 mg, 50 mg, 100 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg, 50 mg, 100 mg, 250 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg, 50 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg</p></div>
<div class="block geq drugH1Div" id="F215962"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F215988"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Pyridoxine HCl Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/mL (per mL): $22.87</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Pyridoxine HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $0.01</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $0.08</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868085"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg/mL (30 mL)</p></div>
<div class="block adm drugH1Div" id="F215982"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer preferably with food and liquid. Bariatric surgery: Tablet, extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. ER tablets should be swallowed whole. Do not break, crush, or chew. IR tablet, capsule, and injectable formulations are available. If safety and efficacy can be effectively monitored, no change in formulation or administration is required after bariatric surgery. Bariatric vitamin supplementation is recommended on a lifelong basis after surgery; may consider integration of daily pyridoxine regimen into the bariatric vitamin in appropriate clinical scenarios.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Injection:</b> Administer IM or IV.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Toxicity secondary to gyromitrin-containing mushrooms (false morel), hydrazine, or isoniazid (off-label uses):</b> Initial doses should be administered IV at a rate of 0.5 to 1 g/minute. If the parenteral formulation is not available, anecdotal reports suggest that pyridoxine tablets may be crushed and made into a slurry and given at the same dose orally or via NG tube (Bateman 2016; Hernon 2019). Oral administration is not recommended for acutely poisoned patients with seizure activity.</p></div>
<div class="block admp drugH1Div" id="F52613751"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer without regard to meals.</p>
<p style="text-indent:-2em;margin-left:4em;">Isoniazid acute ingestion/poisoning: If the parenteral formulation is not available, anecdotal reports suggest that pyridoxine tablets may be crushed and made into a slurry and administered at the same dose orally or via NG tube (Boyer 2006) or an extemporaneous compounded solution may be used. Oral administration is not recommended for acutely poisoned patients with seizure activity.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: May be administered IM or slow IV; seizures have been precipitated following large IV doses.</p>
<p style="text-indent:-2em;margin-left:4em;">Isoniazid toxicity: Initial IV doses should be administered at a rate of 500 to 1,000 mg/minute.</p></div>
<div class="block use drugH1Div" id="F215981"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Pyridoxine deficiency: </b>Treatment and prevention of pyridoxine (vitamin B<sub>6</sub>) deficiency due to inadequate dietary intake, medication use (including isoniazid or oral contraceptives), or inborn errors of metabolism (eg, pyridoxine-dependent convulsions, pyridoxine-responsive anemia).</p></div>
<div class="block off-label drugH1Div" id="F25744561"><span class="drugH1">Use: Off-Label: Adult</span><p>Ethylene glycol poisoning; Gyromitrin-containing mushroom (false morel) overdose/toxicity (treatment/prophylaxis); Hydrazine toxicity; Nausea and vomiting, pregnancy-associated; Neurological toxicities (ie, seizures, coma) associated with isoniazid overdose, prevention; Neurological toxicities (ie, seizures, coma) associated with isoniazid overdose, treatment; Peripheral neuropathy associated with isoniazid therapy for Mycobacterium tuberculosis (prevention)</p></div>
<div class="block mst drugH1Div" id="F216049"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Pyridoxine may be confused with paroxetine, pralidoxime, Pyridium, pyRIDostigmine</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Doxal [Brazil] may be confused with Doxil brand name for DOXOrubicin [U.S.]</p>
<p style="text-indent:-2em;margin-left:4em;">Doxal: Brand name for pyridoxine/thiamine combination [Brazil], but also the brand name for doxepin [Finland]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299968"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F215971"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Altretamine: Pyridoxine may diminish the therapeutic effect of Altretamine. Specifically when altretamine is used in combination with Cisplatin the response duration may be diminished.  Management: Consider avoiding concomitant use of pyridoxine in a altretamine/cisplatin regimen. Although pyridoxine may have beneficial effects on altretamine-associated neurotoxicity, it may reduce the duration of response to altretamine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: Pyridoxine may decrease the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Pyridoxine may diminish the therapeutic effect of Levodopa-Foslevodopa.  Management: The concomitant use of pyridoxine and levodopa (in the absence of a dopa decarboxylase inhibitor (DDI)) should be avoided. Use of a DDI (eg, carbidopa) with levodopa will essentially eliminate the risk of this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">PHENobarbital: Pyridoxine may decrease the serum concentration of PHENobarbital. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Primidone: Pyridoxine may decrease serum concentrations of the active metabolite(s) of Primidone. Specifically, concentrations of phenobarbital may be reduced. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F215989"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Water soluble vitamins cross the placenta (IOM 1998).</p>
<p style="text-indent:0em;margin-top:2em;">Maternal pyridoxine plasma concentrations may decrease as pregnancy progresses and requirements may be increased in pregnant women (IOM 1998).</p>
<p style="text-indent:0em;margin-top:2em;">Pyridoxine is used to treat pregnancy-associated nausea and vomiting (ACOG 2018; Niebyl 2010; SOGC [Campbell 2016]). Pyridoxine is also recommended for the prevention of peripheral neuropathy associated with isoniazid therapy in pregnant patients treated for <i>Mycobacterium tuberculosis</i> (ATS/CDC/IDSA [Nahid 2016]).</p></div>
<div class="block brc drugH1Div" id="F215990"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Pyridoxine is present in breast milk (IOM 1998).</p>
<p style="text-indent:-2em;margin-left:2em;">Breast milk concentrations vary by maternal intake. Pyridoxine requirements are increased in breastfeeding women compared to nonbreastfeeding women (IOM 1998). Possible inhibition of lactation at doses &gt;600 mg/day when taken immediately postpartum (Foukas 1973). Although the manufacturer recommends that caution be exercised when administering pyridoxine injection to breastfeeding women; pyridoxine is considered compatible with breastfeeding (WHO 2002). Pyridoxine is recommended for the prevention of peripheral neuropathy associated with isoniazid therapy in breastfeeding patients treated for <i>Mycobacterium tuberculosis (</i>ATS/CDC/IDSA [Nahid 2016]).</p></div>
<div class="block dic drugH1Div" id="F50930847"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dietary adequate Intake (AI) (IOM 1998): </b></p>
<p style="text-indent:-2em;margin-left:4em;">1 to 6 months: 0.1 mg/day</p>
<p style="text-indent:-2em;margin-left:4em;">7 to 12 months: 0.3 mg/day</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dietary recommended daily allowance (RDA) (IOM 1998):</b></p>
<p style="text-indent:-2em;margin-left:4em;">1 to 3 years: 0.5 mg</p>
<p style="text-indent:-2em;margin-left:4em;">4 to 8 years: 0.6 mg</p>
<p style="text-indent:-2em;margin-left:4em;">9 to 13 years: 1 mg</p>
<p style="text-indent:-2em;margin-left:4em;">14 to 18 years: Females: 1.2 mg; Males: 1.3 mg</p>
<p style="text-indent:-2em;margin-left:4em;">19 to 50 years: 1.3 mg</p>
<p style="text-indent:-2em;margin-left:4em;">≥51 years: Females: 1.5 mg; Males: 1.7 mg</p>
<p style="text-indent:-2em;margin-left:4em;">Pregnancy: 1.9 mg</p>
<p style="text-indent:-2em;margin-left:4em;">Lactation: 2 mg</p></div>
<div class="block mop drugH1Div" id="F5509499"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">For treatment of isoniazid or gyromitrin-containing mushroom toxicity: Anion gap, arterial blood gases, electrolytes, neurological exam, seizure activity.</p>
<p style="text-indent:-2em;margin-left:2em;">For treatment of pyridoxine-dependency syndromes: Signs/symptoms of peripheral neuropathy; consider nerve conduction velocity test every 1 to 2 years in patients on chronic high doses (Coughlin 2021).</p></div>
<div class="block rer drugH1Div" id="F215978"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Plasma pyridoxal 5-phosphate: 5 to 50 mcg/L (SI: 20 to 200 nmol/L) (ESPEN [Berger 2022]).</p></div>
<div class="block pha drugH1Div" id="F215965"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Precursor to pyridoxal, which functions in the metabolism of proteins, carbohydrates, and fats; pyridoxal also aids in the release of liver and muscle-stored glycogen and in the synthesis of GABA (within the central nervous system) and heme</p>
<p style="text-indent:-2em;margin-left:2em;">When used for the treatment of ethylene glycol poisoning, pyridoxine is theorized to increase the formation of glycine, a nontoxic metabolite (Barceloux 1999).</p></div>
<div class="block phk drugH1Div" id="F215985"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Well absorbed (IOM 1998)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic to pyridoxal phosphate and pyridoxamine phosphate (active forms)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Biologic: 15 to 20 days</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (as metabolites)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F215991"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Becilan | Benadon | Pyridoxin | Pyridoxine | Vitamin b6</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Benadon | Tanvimil b6</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Benadon | Vitamin b6</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Bioglan pyridoxine b6 | Blackmores B6 | Cenovis vit b6 | Nature's own vitamin b6 | Naturetime b6 | Pyridoxine | Pyroxin | Vg vitamin b6 | Vit b6 | Vitamin b6 | Vitaplex vit b6 | Vitelle vit b6</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Pyrol | Pyrovit | Sixvit</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Pyridoxine</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Vitamin b6</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">B6 | Neuri b6 | Seis-b | Vitamina B 6 | Vitaminas b6</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Benadon | Burgerstein vitamin b6 | Vitamin B6 Streuli | Vitamine | Vitamine b6</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Vitabe</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Pyridoxine | Vitamin b6</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Benadon | Biprin | Piridoxina | Vitamina b6</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Pyridoxin | Vitamin b6</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">B6 asmedic | B6 vicotrat | Betanum | Bonasanit | Doppelherz vitamin b6 | Hexobion | Naturavegan vitamin b6 | Ntm B6 | Pyragamma | Vitamin b6 | Vitamin b6 hevert</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Vitamina b6</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Benadon | Beneuron</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">B6-vitamiin ns | Pyridoxin hcl | Vita B6 | Vitamin b6 | Vitatabs b6</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Benadon | Godabion b6 | Vitamina b6 bayer</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">B-heksin | Heksavit | Vita B6</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Becilan | Pyridoxine labaz | Vitamine b6 richard</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Benadon | Crookes | Orovite comploment | Paxadon | Pyridoxine | Pyridoxine cox | Pyridoxine napp | Pyridoxine roche | Pyridoxine zanza | Replavite | Valupak vitamin b6 | Vitalife vit b6 | Vitamin b6</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Besix</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Neo active vitamin b6 | Pyribion | Pyrixin | Vitamin b6</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Beres b6 vitamin | Vitamin b6</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Bonasanit | Liconam | Pyridoxine | Pyridoxine(b) | Pyridoxini hcl | Vitamin b6</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Lifeplan b6 | Pyridoxine | Seven seas vitamin b6 | Sona vitamin b6</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Anacrodyne | B six</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">B-long | Becosix | Benadon | Pyricontin | Pyrodur</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Pyridoxine (b6) kindi | Samavit b6</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Benadon | Vitamina b6 | Xanturenasi</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">B6 | Benadon</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Aderoxin torii | Aderoxin wakodo | Be six | Bihexane sanken | Sixar | Vitamin b6 f</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Pyridoxine</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Pyridoxine | Pyridoxine sinil</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Pyridoxin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Benadon | Jamieson Vitamin B6 | Vitamin b6</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Pyridoxin | Pyridoxin hcl | Vita B6 | Vitamin b6</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Pyridoxin | Pyridoxin hcl | Vitamin b6 | Vitamin b6 sopharma | Vitatabs b6</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Pyrydox</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Prime B6 | Prydox | Pyridomin | Pyridoxine | Pyridoxine-10 | Trio-vitamin b6 | Upha B6 | Vitamin b6</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Emzor vitamin b6 | Surelife vitamin b6</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Pyridoxine HCL | Pyridoxine Hcl PCH</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">B6 vicotrat | Benadon | Pyridoksin naf | Pyridoxin</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Apo-pyridoxine | Solgar vitamin b6 | Vitamin b6 | Vitaminn b6</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">GNC Vitamin b-6 | Piridoxina | Sundown naturals b6</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Amdoxine | B6 | Pyro 6 | Trovit-6 | V-six | Veri-6 | Vita 6</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Pyridoxin | Vitamin b6 | Vitamin b6-ratiopharm | Vitaminum b6</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Pyridoxine HCL | Vitamin b6</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Benadon | Piridoxina</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Vitamin b6</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Pyridoxin | Sentinel Vitamin B-6</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Vitamina b6 | Vitamina b6 zentiva</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Pyridoxin | Pyridoxin hydrochloride | Vitamin b6</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Pyridoxin | Pyridoxine</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Pyridoxin Recip</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Pyridomin | Pyridoxine | Vitamin b6</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Vitamin b6 | Vitamin B6 Jenapharm</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Plivit b6 | Pyridoxin | Vitamin b6</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">B six p | Benadon | Besix | Biovit b6 | Jotexin | Med-b6 | Mega-b | Pyridon-f | Pyridoxine | Vitamin b6</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Becilan</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">B6 vigen | Libavit b6</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Active-b6 | Beesix | Pyrdioxine | Pyridoxine | Pyridoxine HCL | Unibisix | Vitamin b6</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Pyridoxin | Vitamin b6</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Agovit 6 | Pyri | Pyriren</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Benadon</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Benadon | Biprin | Suprabion | Vitamina b6</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Be-tabs pyridoxine hcl | Beesix | Egoli pyridoxine | Lactosec | No lactin | Pyridoxine | Pyridoxine HCL | Vitamin b6</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Be-tabs pyridoxine hcl | Besix | Bisix | Kamvit 6</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Beesix</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-2823181">
<a name="2823181"></a>Albin RL, Albers JW, Greensberg HS, et al. Acute Sensory Neuropathy - Neuronopathy From Pyridoxine Overdose. <i>Neurology</i>. 1987;37(11):1729-1732.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/2823181/pubmed" id="2823181" target="_blank">2823181</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Aluminum in large and small volume parenterals used in total parenteral nutrition. <i>Fed Regist</i>. 2002;67(244):77792-77793. To be codified at 21 CFR §201.323.</div>
</li>
<li>
<div class="reference">
                  American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2018 Report of the Committee on Infectious Diseases</i>. 31st ed. American Academy of Pediatrics; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29266076">
<a name="29266076"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 189: Nausea and vomiting of pregnancy. <i>Obstet Gynecol</i>. 2018;131(1):e15-e30. doi:10.1097/AOG.0000000000002456<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/29266076/pubmed" id="29266076" target="_blank">29266076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10497633">
<a name="10497633"></a>Barceloux DG, Krenzelok EP, Olson K, Watson W. American Academy of Clinical Toxicology practice guidelines on the treatment of ethylene glycol poisoning. Ad Hoc Committee. <i>J Toxicol Clin Toxicol</i>. 1999;37(5):537-560.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/10497633/pubmed" id="10497633" target="_blank">10497633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26255881">
<a name="26255881"></a>Bateman DN, Page CB. Antidotes to coumarins, isoniazid, methotrexate and thyroxine, toxins that work via metabolic processes. <i>Br J Clin Pharmacol</i>. 2016;81(3):437-445. doi:10.1111/bcp.12736<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/26255881/pubmed" id="26255881" target="_blank">26255881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10519720">
<a name="10519720"></a>Baxter P. Epidemiology of pyridoxine dependent and pyridoxine responsive seizures in the UK. <i>Arch Dis Child</i>. 1999;81(5):431-433.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/10519720/pubmed" id="10519720" target="_blank">10519720</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15707814">
<a name="15707814"></a>Berger KJ, Guss DA. Mycotoxins revisited: Part II. <i>J Emerg Med</i>. 2005;28(2):175-183.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/15707814/pubmed" id="15707814" target="_blank">15707814</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35365361">
<a name="35365361"></a>Berger MM, Shenkin A, Schweinlin A, et al. ESPEN micronutrient guideline. <i>Clin Nutr</i>. 2022;41(6):1357-1424. doi:10.1016/j.clnu.2022.02.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/35365361/pubmed" id="35365361" target="_blank">35365361</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Boyer EW. Antituberculous medications. In: Flomenbaum NE, Goldfrank LR, Hoffman, RS, et al, eds. <i>Goldfrank's Toxicologic Emergencies</i>. 8th ed. McGraw-Hill; 2006.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27986189">
<a name="27986189"></a>Campbell K, Rowe H, Azzam H, Lane CA. The management of nausea and vomiting of pregnancy. <i>J Obstet Gynaecol Can</i>. 2016;38(12):1127-1137. doi:10.1016/j.jogc.2016.08.009.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/27986189/pubmed" id="27986189" target="_blank">27986189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33200442">
<a name="33200442"></a>Coughlin CR 2nd, Tseng LA, Abdenur JE, et al. Consensus guidelines for the diagnosis and management of pyridoxine-dependent epilepsy due to α-aminoadipic semialdehyde dehydrogenase deficiency. <i>J Inherit Metab Dis</i>. 2021;44(1):178-192. doi:10.1002/jimd.12332<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/33200442/pubmed" id="33200442" target="_blank">33200442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28669553">
<a name="28669553"></a>Dart RC, Goldfrank LR, Erstad BL, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. <i>Ann Emerg Med</i>. 2018;71(3):314-325. doi:10.1016/j.annemergmed.2017.05.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/28669553/pubmed" id="28669553" target="_blank">28669553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15699849">
<a name="15699849"></a>Diaz JH. Syndromic Diagnosis and Management of Confirmed Mushroom Poisonings. <i>Crit Care Med</i>. 2005;33(2):427-436.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/15699849/pubmed" id="15699849" target="_blank">15699849</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31144371">
<a name="31144371"></a>DiBaise M, Tarleton SM. Hair, nails, and skin: differentiating cutaneous manifestations of micronutrient deficiency.<i> Nutr Clin Pract</i>. 2019;34(4):490-503. doi:10.1002/ncp.10321<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/31144371/pubmed" id="31144371" target="_blank">31144371</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4579974">
<a name="4579974"></a>Foukas MD. An Antilactogenic Effect of Pyridoxine. <i>J Obstet Gynaecol BrCommonw</i>. 1973;80(8):718-720.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/4579974/pubmed" id="4579974" target="_blank">4579974</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14334180">
<a name="14334180"></a>Frierson WB. Use of pyridoxine HCl in acute hydrazine and UDMH intoxication. <i>Ind Med Surg</i>. 1965;34:650-651.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/14334180/pubmed" id="14334180" target="_blank">14334180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gal.2007">
<a name="Gal.2007"></a>Gal P, Reed M. Medications. In: Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Saunders Elsevier; 2007:2955-2999.</div>
</li>
<li>
<div class="reference">
                  Goldfrank LR. Mushrooms. In: Nelson LS, Howland MA, Lewin NA, Smith SW, Goldfrank, Hoffman RS, eds. <i>Goldfrank's Toxicologic Emergencies</i>. 11th ed. McGraw-Hill; 2019;1581-1596.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3008620">
<a name="3008620"></a>Harati Y, Niakan E. Hydrazine toxicity, pyridoxine therapy, and peripheral neuropathy. <i>Ann Intern Med</i>. 1986;104(5):728-729. doi:10.7326/0003-4819-104-5-728_2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/3008620/pubmed" id="3008620" target="_blank">3008620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hernon.2015a">
<a name="Hernon.2015a"></a>Hernon CH. Antituberculous medications. In: Hoffman RS, Howland M, Lewin NA, Nelson LS, Goldfrank LR, eds. <i>Goldfrank's Toxicologic Emergencies</i>, 10 ed. McGraw-Hill; 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hernon.2015">
<a name="Hernon.2015"></a>Hernon CH, Lai JT. Antituberculous medications. In: Nelson LS, Howland MA, Lewin NA, Smith SW, Goldfrank, Hoffman RS, eds. <i>Goldfrank's Toxicologic Emergencies</i>. 11th ed. McGraw-Hill; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Howland.2015">
<a name="Howland.2015"></a>Howland MA. Antidotes in depth: pyridoxine. In: Nelson LS, Howland MA, Lewin NA, Smith SW, Goldfrank, Hoffman RS, eds. <i>Goldfrank's Toxicologic Emergencies</i>. 11th ed. McGraw-Hill; 2019.</div>
</li>
<li>
<div class="reference">
                  IOM (Institute of Medicine). <i>Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B</i><sub>6</sub><i>, Folate, Vitamin B</i><sub>12</sub><i>, Pantothenic Acid, Biotin, and Choline.</i> The National Academies Press; 1998.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19357635">
<a name="19357635"></a>Kaplan JE, Benson C, Holmes KK, Brooks JT, Pau A, Masur H; Centers for Disease Control and Prevention (CDC); National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <i>MMWR Recomm Rep</i>. 2009;58(RR-4):1-207; quiz CE1-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/19357635/pubmed" id="19357635" target="_blank">19357635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-815813">
<a name="815813"></a>Kirklin JK, Watson M, Bondoc CC, Burke JF. Treatment of hydrazine-induced coma with pyridoxine. <i>N Engl J Med</i>. 1976;294(17):938-939. doi:10.1056/NEJM197604222941708<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/815813/pubmed" id="815813" target="_blank">815813</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15756083">
<a name="15756083"></a>Lheureux P, Penaloza A, Gris M. Pyridoxine in clinical toxicology: a review. <i>Eur J Emerg Med</i>. 2005;12(2):78-85. doi:10.1097/00063110-200504000-00007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/15756083/pubmed" id="15756083" target="_blank">15756083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7750075">
<a name="7750075"></a>McLachlan RS, Brown WF. Pyridoxine dependent epilepsy with iatrogenic sensory neuronopathy. <i>Can J Neurol Sci</i>. 1995;22(1):50-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/7750075/pubmed" id="7750075" target="_blank">7750075</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16999664">
<a name="16999664"></a>Morrow LE, Wear RE, Schuller D, et al. Acute isoniazid toxicity and the need for adequate pyridoxine supplies. <i>Pharmacotherapy</i>. 2006;26(10):1529-1532.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/16999664/pubmed" id="16999664" target="_blank">16999664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10890675">
<a name="10890675"></a>Nagappan R, Riddell T. Pyridoxine therapy in a patient with severe hydrazine sulfate toxicity. <i>Crit Care Med</i>. 2000;28(6):2116-2118. doi:10.1097/00003246-200006000-00076<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/10890675/pubmed" id="10890675" target="_blank">10890675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27516382">
<a name="27516382"></a>Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. <i>Clin Infect Dis</i>. 2016;63(7):e147-e195. doi:10.1093/cid/ciw376<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/27516382/pubmed" id="27516382" target="_blank">27516382</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  National Organization for Rare Disorders (NORD). Pyridoxine-Dependent Epilepsy. https://rarediseases.org/rare-diseases/pyridoxine-dependent-epilepsy. Updated 2017. Accessed March 11, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20942670">
<a name="20942670"></a>Niebyl JR. Clinical practice. Nausea and vomiting in pregnancy. <i>N Engl J Med</i>. 2010;363(16):1544-1550. doi:10.1056/NEJMcp1003896<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/20942670/pubmed" id="20942670" target="_blank">20942670</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Pyridoxine injection [prescribing information]. Lake Zurich, IL: Fresenius Kabi; September 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18506894">
<a name="18506894"></a>Roberts EA, Schilsky ML, and American Association for Study of Liver Diseases (AASLD). Diagnosis and treatment of Wilson disease: an update. <i>Hepatology</i>. 2008;47(6):2089-2111.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/18506894/pubmed" id="18506894" target="_blank">18506894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10220077">
<a name="10220077"></a>Santucci KA, Shah BR, Linakis JG. Acute Isoniazid Exposures and Antidote Availability. <i>Pediatric Emergency Care</i>. 1999;15(2):99-101.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/10220077/pubmed" id="10220077" target="_blank">10220077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Smith.1">
<a name="Smith.1"></a>Smith JA, Fox KA, Clark SM. Nausea and vomiting of pregnancy: treatment and outcome. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed November 2, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21704546">
<a name="21704546"></a>Stockler S, Plecko B, Gospe SM Jr, et al. Pyridoxine dependent epilepsy and antiquitin deficiency: clinical and molecular characteristics and recommendations for diagnosis, treatment and follow-up. <i>Mol Genet Metab</i>. 2011;104(1-2):48-60.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/21704546/pubmed" id="21704546" target="_blank">21704546</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Accessed May 5, 2020.</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/pediatric-oi/tables-pediatric-oi.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/pediatric-oi/tables-pediatric-oi.pdf</a>.Updated December 9, 2019. Accessed March 5, 2020.</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services (HHS) Panel on Adult and Adolescent Opportunistic Infection. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Updated November 21, 2019. Accessed March 5, 2020.</div>
</li>
<li>
<div class="reference">
                  Vitamin B6 [prescribing information]. Long Island City: NY: Freeda Vitamins Inc; received June 2011.</div>
</li>
<li>
<div class="reference">
                  Vitamin B-6 (pyridoxine) [prescribing information]. Livonia: MI: Rugby Laboratories; November 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32822230">
<a name="32822230"></a>Vossler DG, Bainbridge JL, Boggs JG, et al. Treatment of refractory convulsive status epilepticus: a comprehensive review by the American Epilepsy Society Treatments Committee. <i>Epilepsy Curr</i>. 2020;20(5):245-264. doi:10.1177/1535759720928269<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/32822230/pubmed" id="32822230" target="_blank">32822230</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  World Health Organization (WHO). WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment. https://www.who.int/publications/i/item/9789240007048. Published 2020.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9839 Version 303.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
